Symbols / LPCN
LPCN Chart
About
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 52.35M |
| Enterprise Value | 37.38M | Income | -5.48M | Sales | 4.32M |
| Book/sh | 2.61 | Cash/sh | 2.73 | Dividend Yield | — |
| Payout | 0.00% | Employees | 16 | IPO | — |
| P/E | — | Forward P/E | -7.60 | PEG | — |
| P/S | 12.11 | P/B | 3.61 | P/C | — |
| EV/EBITDA | -5.98 | EV/Sales | 8.65 | Quick Ratio | 7.89 |
| Current Ratio | 8.25 | Debt/Eq | 1.11 | LT Debt/Eq | — |
| EPS (ttm) | -1.02 | EPS next Y | -1.24 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 08:00 | ROA | -21.45% |
| ROE | -32.92% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -29.34% | Profit Margin | -126.66% | Shs Outstand | 5.55M |
| Shs Float | 4.86M | Short Float | 2.38% | Short Ratio | 0.66 |
| Short Interest | — | 52W High | 12.37 | 52W Low | 2.52 |
| Beta | 1.01 | Avg Volume | 123.14K | Volume | 194.89K |
| Target Price | $10.88 | Recom | None | Prev Close | $9.50 |
| Price | $9.43 | Change | -0.74% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.88
Mean price target
2. Current target
$9.43
Latest analyst target
3. DCF / Fair value
$-10.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.43
Low
$6.75
High
$15.00
Mean
$10.88
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-11-13 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-20 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-06-27 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-06-10 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-07-27 | reit | Cantor Fitzgerald | Overweight → Overweight | $33 |
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PR Newswire hu, 06 Nov 2025 08
- Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Yahoo Finance Wed, 11 Feb 2026 08
- Lipocine (LPCN) Price Target Increased by 58.18% to 11.09 - Nasdaq Wed, 04 Feb 2026 08
- Lipocine Stock Jump Looks Great, But How Secure Is That Gain? - Trefis hu, 27 Nov 2025 08
- Lipocine Updates Investor Presentation to Reflect Latest Strategy - TipRanks Wed, 18 Feb 2026 14
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire ue, 20 Jan 2026 08
- H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com Wed, 21 Jan 2026 08
- Aug Drivers: Will LPCN stock recover after earnings - July 2025 Spike Watch & Daily Technical Stock Forecast Reports - baoquankhu1.vn Sat, 21 Feb 2026 16
- LPCN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI ue, 13 May 2025 21
- symbol__ Stock Quote Price and Forecast - CNN Sat, 02 Mar 2024 05
- Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance hu, 06 Nov 2025 08
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire Mon, 12 Jan 2026 08
- Will LPCN stock outperform growth indexes - Quarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - mfd.ru Wed, 11 Feb 2026 13
- Quarterly Earnings: Will LPCN stock go up in YEAR - Portfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn hu, 19 Feb 2026 01
- LPCN: 1154 Results Illuminate Accelerated Pathway - Zacks Small Cap Research Fri, 19 May 2023 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4893 | — | — | Stock Award(Grant) at price 0.00 per share. | PATEL MAHESH V | Chief Executive Officer | — | 2024-03-08 00:00:00 | D |
| 1 | 991 | — | — | Stock Award(Grant) at price 0.00 per share. | FOGARTY KRISTA | Officer | — | 2024-03-08 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.29K | 44.66K | 171.35K | -983.91K |
| TaxRateForCalcs | 0.08 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -1.13M | -18.11M | -11.54M | 3.21M |
| TotalUnusualItems | 17.17K | 212.69K | 815.94K | -3.64M |
| TotalUnusualItemsExcludingGoodwill | 17.17K | 212.69K | 815.94K | -3.64M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 8.35K | -16.35M | -10.76M | -634.40K |
| ReconciledDepreciation | 41.11K | 28.66K | 9.45K | 380.00 |
| ReconciledCostOfRevenue | 7.35M | 10.18M | 8.56M | 7.67M |
| EBITDA | -1.11M | -17.90M | -10.72M | -430.53K |
| EBIT | -1.16M | -17.93M | -10.73M | -430.91K |
| NetInterestIncome | 1.15M | 1.37M | 545.48K | -135.59K |
| InterestExpense | 0.00 | 27.10K | 203.29K | |
| InterestIncome | 1.15M | 1.37M | 572.58K | 67.70K |
| NormalizedIncome | -7.52K | -16.52M | -11.40M | 2.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 8.35K | -16.35M | -10.76M | -634.40K |
| TotalExpenses | 12.35M | 15.08M | 12.62M | 13.00M |
| TotalOperatingIncomeAsReported | -1.16M | -17.93M | -12.12M | 3.15M |
| DilutedAverageShares | 5.42M | 5.27M | 5.23M | 5.11M |
| BasicAverageShares | 5.34M | 5.27M | 5.20M | 5.11M |
| DilutedEPS | 0.00 | -3.14 | -2.21 | -0.17 |
| BasicEPS | 0.00 | -3.10 | -2.04 | -0.17 |
| DilutedNIAvailtoComStockholders | -8.81K | -16.56M | -11.32M | -634.40K |
| AverageDilutionEarnings | -17.17K | -212.69K | -565.94K | |
| NetIncomeCommonStockholders | 8.35K | -16.35M | -10.76M | -634.40K |
| PreferredStockDividends | 89.00 | |||
| NetIncome | 8.35K | -16.35M | -10.76M | -634.40K |
| NetIncomeIncludingNoncontrollingInterests | 8.35K | -16.35M | -10.76M | -634.40K |
| NetIncomeContinuousOperations | 8.35K | -16.35M | -10.76M | -634.40K |
| TaxProvision | 681.00 | 755.00 | 681.00 | 200.00 |
| PretaxIncome | 9.03K | -16.35M | -10.76M | -634.20K |
| OtherIncomeExpense | 17.17K | 212.69K | 815.94K | -3.64M |
| SpecialIncomeCharges | 0.00 | 250.00K | -4.00M | |
| OtherSpecialCharges | -250.00K | 4.00M | ||
| GainOnSaleOfSecurity | 17.17K | 212.69K | 565.94K | 355.89K |
| NetNonOperatingInterestIncomeExpense | 1.15M | 1.37M | 545.48K | -135.59K |
| InterestExpenseNonOperating | 0.00 | 27.10K | 203.29K | |
| InterestIncomeNonOperating | 1.15M | 1.37M | 572.58K | 67.70K |
| OperatingIncome | -1.16M | -17.93M | -12.12M | 3.15M |
| OperatingExpense | 5.00M | 4.90M | 4.06M | 5.33M |
| SellingGeneralAndAdministration | 5.00M | 4.90M | 4.06M | 5.33M |
| GeneralAndAdministrativeExpense | 5.00M | 4.90M | 4.06M | 5.33M |
| OtherGandA | 5.00M | 4.90M | 4.06M | 5.33M |
| GrossProfit | 3.85M | -13.03M | -8.06M | 8.48M |
| CostOfRevenue | 7.35M | 10.18M | 8.56M | 7.67M |
| TotalRevenue | 11.20M | -2.85M | 500.00K | 16.14M |
| OperatingRevenue | 11.20M | -2.85M | 500.00K | 16.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 336.00 | 336.00 | 335.00 | 335.00 |
| OrdinarySharesNumber | 5.35M | 5.32M | 5.21M | 5.19M |
| ShareIssued | 5.35M | 5.32M | 5.21M | 5.19M |
| TotalDebt | 2.31M | |||
| TangibleBookValue | 21.00M | 20.37M | 35.63M | 45.57M |
| InvestedCapital | 21.00M | 20.37M | 35.63M | 47.88M |
| WorkingCapital | 20.81M | 20.23M | 32.46M | 40.76M |
| NetTangibleAssets | 21.00M | 20.37M | 35.63M | 45.57M |
| CommonStockEquity | 21.00M | 20.37M | 35.63M | 45.57M |
| TotalCapitalization | 21.00M | 20.37M | 35.63M | 45.57M |
| TotalEquityGrossMinorityInterest | 21.00M | 20.37M | 35.63M | 45.57M |
| StockholdersEquity | 21.00M | 20.37M | 35.63M | 45.57M |
| GainsLossesNotAffectingRetainedEarnings | 9.14K | 7.26K | -20.32K | -18.02K |
| OtherEquityAdjustments | 9.14K | 7.26K | -20.32K | -18.02K |
| TreasuryStock | 40.71K | 40.71K | 40.71K | 40.71K |
| RetainedEarnings | -199.77M | -199.78M | -183.43M | -172.67M |
| AdditionalPaidInCapital | 220.79M | 220.17M | 219.11M | 218.29M |
| CapitalStock | 8.86K | 8.86K | 8.85K | 8.83K |
| CommonStock | 8.86K | 8.86K | 8.85K | 8.83K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 1.51M | 2.63M | 1.91M | 6.91M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 229.86K | 1.30M |
| OtherNonCurrentLiabilities | 500.00K | |||
| DerivativeProductLiabilities | 0.00 | 229.86K | 795.80K | |
| CurrentLiabilities | 1.51M | 2.63M | 1.68M | 5.62M |
| OtherCurrentLiabilities | 17.17K | 1.00M | ||
| CurrentDeferredLiabilities | 320.00K | 0.00 | ||
| CurrentDeferredRevenue | 320.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 2.31M | |||
| CurrentDebt | 2.31M | |||
| PayablesAndAccruedExpenses | 1.19M | 2.61M | 1.68M | 2.31M |
| CurrentAccruedExpenses | 921.24K | 1.22M | 1.08M | 1.02M |
| Payables | 271.70K | 1.40M | 600.39K | 1.29M |
| AccountsPayable | 271.70K | 1.40M | 600.39K | 1.29M |
| TotalAssets | 22.51M | 23.00M | 37.54M | 52.48M |
| TotalNonCurrentAssets | 188.83K | 139.85K | 3.41M | 6.10M |
| OtherNonCurrentAssets | 23.75K | 23.75K | 23.75K | 23.75K |
| NonCurrentDeferredAssets | 4.05M | |||
| NonCurrentAccountsReceivable | 3.25M | 4.05M | ||
| InvestmentsAndAdvances | 0.00 | 2.02M | ||
| InvestmentinFinancialAssets | 0.00 | 2.02M | ||
| AvailableForSaleSecurities | 2.02M | |||
| NetPPE | 165.07K | 116.09K | 131.59K | 7.21K |
| AccumulatedDepreciation | -1.22M | -1.18M | -1.15M | -1.14M |
| GrossPPE | 1.39M | 1.30M | 1.29M | 1.15M |
| MachineryFurnitureEquipment | 1.39M | 1.30M | 1.29M | 1.15M |
| CurrentAssets | 22.32M | 22.86M | 34.14M | 46.38M |
| OtherCurrentAssets | 567.91K | 773.42K | 945.32K | 1.51M |
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 1.51M | |||
| Receivables | 120.45K | 52.25K | 659.86K | 247.25K |
| OtherReceivables | 579.43K | |||
| AccruedInterestReceivable | 120.45K | 52.25K | 80.43K | 247.25K |
| CashCashEquivalentsAndShortTermInvestments | 21.63M | 22.04M | 32.53M | 44.62M |
| OtherShortTermInvestments | 15.43M | 17.26M | 29.38M | 41.67M |
| CashAndCashEquivalents | 6.21M | 4.77M | 3.15M | 2.95M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -1.31M | -11.88M | -12.10M | -4.42M |
| RepurchaseOfCapitalStock | -21.70K | |||
| RepaymentOfDebt | 0.00 | -2.32M | -3.33M | |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 209.34K | 404.57K | 0.00 | 30.25M |
| CapitalExpenditure | -90.09K | -13.17K | -133.83K | -7.59K |
| InterestPaidSupplementalData | 0.00 | 21.26K | 149.54K | |
| IncomeTaxPaidSupplementalData | 681.00 | 225.00 | 200.00 | 200.00 |
| EndCashPosition | 6.21M | 4.77M | 3.15M | 2.95M |
| BeginningCashPosition | 4.77M | 3.15M | 2.95M | 24.22M |
| ChangesInCash | 1.43M | 1.62M | 197.94K | -21.27M |
| FinancingCashFlow | 209.34K | 404.57K | -2.13M | 26.92M |
| CashFlowFromContinuingFinancingActivities | 209.34K | 404.57K | -2.13M | 26.92M |
| ProceedsFromStockOptionExercised | 0.00 | 211.42K | 11.69K | |
| NetCommonStockIssuance | 209.34K | 404.57K | -21.70K | 30.25M |
| CommonStockPayments | -21.70K | |||
| CommonStockIssuance | 209.34K | 404.57K | 0.00 | 30.25M |
| NetIssuancePaymentsOfDebt | 0.00 | -2.32M | -3.33M | |
| NetLongTermDebtIssuance | 0.00 | -2.32M | -3.33M | |
| LongTermDebtPayments | 0.00 | -2.32M | -3.33M | |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 2.45M | 13.08M | 14.29M | -43.78M |
| CashFlowFromContinuingInvestingActivities | 2.45M | 13.08M | 14.29M | -43.78M |
| NetInvestmentPurchaseAndSale | 2.54M | 13.10M | 14.43M | -43.77M |
| SaleOfInvestment | 35.40M | 36.00M | 59.50M | 4.65M |
| PurchaseOfInvestment | -32.86M | -22.90M | -45.07M | -48.42M |
| NetPPEPurchaseAndSale | -90.09K | -13.17K | -133.83K | -7.59K |
| PurchaseOfPPE | -90.09K | -13.17K | -133.83K | -7.59K |
| OperatingCashFlow | -1.22M | -11.87M | -11.97M | -4.41M |
| CashFlowFromContinuingOperatingActivities | -1.22M | -11.87M | -11.97M | -4.41M |
| ChangeInWorkingCapital | -964.21K | 2.01M | -923.63K | -4.59M |
| ChangeInOtherWorkingCapital | 320.00K | |||
| ChangeInOtherCurrentLiabilities | 0.00 | -1.25M | 1.50M | |
| ChangeInPayablesAndAccruedExpense | -1.42M | 936.34K | -627.67K | -944.60K |
| ChangeInAccruedExpense | -297.25K | 140.75K | 61.28K | -636.72K |
| ChangeInPayable | -1.12M | 795.59K | -688.95K | -307.88K |
| ChangeInAccountPayable | -1.12M | 795.59K | -688.95K | -307.88K |
| ChangeInPrepaidAssets | 205.51K | 333.08K | 569.15K | -853.21K |
| ChangeInReceivables | -68.19K | 738.11K | 384.90K | -4.30M |
| OtherNonCashItems | -244.16K | 53.75K | ||
| StockBasedCompensation | 408.55K | 654.44K | 636.14K | 603.95K |
| AssetImpairmentCharge | 0.00 | 2.96M | 0.00 | |
| AmortizationOfSecurities | -697.87K | -952.65K | -122.05K | 515.58K |
| DepreciationAmortizationDepletion | 41.11K | 28.66K | 9.45K | 380.00 |
| DepreciationAndAmortization | 41.11K | 28.66K | 9.45K | 380.00 |
| Depreciation | 41.11K | 28.66K | 9.45K | 380.00 |
| OperatingGainsLosses | -17.17K | -212.69K | -565.94K | -355.89K |
| GainLossOnInvestmentSecurities | -17.17K | -212.69K | -565.94K | -355.89K |
| NetIncomeFromContinuingOperations | 8.35K | -16.35M | -10.76M | -634.40K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LPCN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|